CN105012356B - Purposes of the ganoderic acid A in depression - Google Patents
Purposes of the ganoderic acid A in depression Download PDFInfo
- Publication number
- CN105012356B CN105012356B CN201410197934.9A CN201410197934A CN105012356B CN 105012356 B CN105012356 B CN 105012356B CN 201410197934 A CN201410197934 A CN 201410197934A CN 105012356 B CN105012356 B CN 105012356B
- Authority
- CN
- China
- Prior art keywords
- ganoderic acid
- depression
- drug
- acid
- ganoderic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 title claims abstract description 108
- BSEYIQDDZBVTJY-UHFFFAOYSA-N Ganoderic acid A Natural products CC(CC(=O)CCC1CC(O)C2(C)C3=C(C(=O)CC12C)C4(C)CCC(=O)C(C)(C)C4CC3O)C(=O)O BSEYIQDDZBVTJY-UHFFFAOYSA-N 0.000 title claims abstract description 86
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 36
- 239000003814 drug Substances 0.000 claims abstract description 34
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 21
- 150000002148 esters Chemical class 0.000 claims abstract description 10
- 229930182478 glucoside Natural products 0.000 claims abstract description 10
- 150000008131 glucosides Chemical class 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 239000004615 ingredient Substances 0.000 claims abstract description 9
- 239000007924 injection Substances 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 230000001430 anti-depressive effect Effects 0.000 abstract description 22
- 230000008901 benefit Effects 0.000 abstract description 3
- 206010003591 Ataxia Diseases 0.000 abstract description 2
- 206010010947 Coordination abnormal Diseases 0.000 abstract description 2
- 229940000406 drug candidate Drugs 0.000 abstract description 2
- 206010015037 epilepsy Diseases 0.000 abstract description 2
- 208000016290 incoordination Diseases 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000001939 inductive effect Effects 0.000 abstract 1
- 240000008397 Ganoderma lucidum Species 0.000 description 29
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 29
- 238000012360 testing method Methods 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 229930182735 Ganoderic acid Natural products 0.000 description 19
- 229940005513 antidepressants Drugs 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 241000222336 Ganoderma Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 229960004801 imipramine Drugs 0.000 description 10
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 10
- 241000207961 Sesamum Species 0.000 description 9
- 235000003434 Sesamum indicum Nutrition 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000009182 swimming Effects 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000012048 forced swim test Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 150000003648 triterpenes Chemical class 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000581650 Ivesia Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- -1 triterpene compound Chemical class 0.000 description 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- KASALCUNLBTNAA-LIPCCPSCSA-N Ganodermanontriol Chemical compound CC1(C)C(=O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CC[C@H](O)[C@](C)(O)CO)C)CC[C@@]4(C)C3=CC[C@H]21 KASALCUNLBTNAA-LIPCCPSCSA-N 0.000 description 2
- JPLNPSCODMUBRP-UHFFFAOYSA-N Ganodermanontriol Natural products CC(CCCC(O)(CO)CO)C1CCC2(C)C3=CCC4C(C)(C)C(=O)CCC4(C)C3=CCC12C JPLNPSCODMUBRP-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000222341 Polyporaceae Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 231100000753 hepatic injury Toxicity 0.000 description 2
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 2
- 229960002102 imipramine hydrochloride Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- ZTKZZRIVAYGFSF-UHFFFAOYSA-N 3,7-Dioxo-8,24Z-tirucalladien-26-oic acid Natural products CC12CCC(=O)C(C)(C)C1CC(=O)C1=C2CCC2(C)C(C(CCC=C(C)C(O)=O)C)CCC21C ZTKZZRIVAYGFSF-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LWPLEHFGBRFRKI-NBCWKOIPSA-N Ganoderic acid B Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)C[C@@H](C)C(O)=O)C)CC(=O)[C@]21C LWPLEHFGBRFRKI-NBCWKOIPSA-N 0.000 description 1
- LWPLEHFGBRFRKI-CQKTXKLZSA-N Ganoderic acid B Natural products C[C@H](CC(=O)C[C@H](C)C(=O)O)[C@H]1CC(=O)[C@@]2(C)C3=C(C(=O)C[C@]12C)[C@@]4(C)CC[C@H](O)C(C)(C)[C@H]4C[C@@H]3O LWPLEHFGBRFRKI-CQKTXKLZSA-N 0.000 description 1
- RERVSJVGWKIGTJ-RQLZKMEDSA-N Ganoderic acid C2 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)C[C@@H](C)C(O)=O)C)C[C@H](O)[C@]21C RERVSJVGWKIGTJ-RQLZKMEDSA-N 0.000 description 1
- QIYPKRHGDIQKEC-WWQYYNNASA-N Ganoderic acid DM Natural products C[C@H](CCC=C(/C)C(=O)O)[C@H]1CC[C@@H]2[C@@H]1CCC3=C2C(=O)C[C@H]4C(C)(C)C(=O)CC[C@]34C QIYPKRHGDIQKEC-WWQYYNNASA-N 0.000 description 1
- ZTKZZRIVAYGFSF-PIPDTRPPSA-N Ganoderic acid DM Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CC(=O)C1=C2CC[C@]2(C)[C@@H]([C@@H](CC\C=C(/C)C(O)=O)C)CC[C@]21C ZTKZZRIVAYGFSF-PIPDTRPPSA-N 0.000 description 1
- 241001489091 Ganoderma sinense Species 0.000 description 1
- AAJIHHYEPHRIET-XEFAKFPISA-N Ganodermanondiol Chemical compound CC1(C)C(=O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CC[C@H](O)C(C)(C)O)C)CC[C@@]4(C)C3=CC[C@H]21 AAJIHHYEPHRIET-XEFAKFPISA-N 0.000 description 1
- YTQAKTDSTUEPNZ-JREPXQSNSA-N Ganodermanondiol Natural products C[C@H](CC[C@H](C)C(C)(C)O)[C@H]1CC[C@@]2(C)C3=CC[C@H]4C(C)(C)C(=O)CC[C@]4(C)C3=CC[C@]12C YTQAKTDSTUEPNZ-JREPXQSNSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000001720 action spectrum Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229930193921 lucidenic acid Natural products 0.000 description 1
- VZYPWBVGOUSGOD-KEUIGMMSSA-N lucidenic acid A Natural products COC(=O)CC[C@@H](C)[C@H]1CC[C@@]2(C)C3=C(C(=O)C[C@]12C)[C@@]4(C)CCC(=O)C(C)(C)[C@@H]4C[C@@H]3O VZYPWBVGOUSGOD-KEUIGMMSSA-N 0.000 description 1
- INIPQDKLXQHEAJ-RGGGUVNYSA-N lucidenic acid a Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@H]1C[C@H](O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CCC(O)=O)C)CC(=O)[C@]21C INIPQDKLXQHEAJ-RGGGUVNYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
" purposes of the ganoderic acid A in depression " of the invention belongs to pharmaceutical field, it is characterized in that, the medicament of depression is used to prepare using the derivative of ganoderic acid A or ganoderic acid A as drug activity ingredient, the derivative refers to glucoside formed by the salt, ester or sugar of ganoderic acid A and pharmaceutical acceptable.The medicament can be used to treat or prevention of depression, have many advantages, such as that antidepressant effect is notable, quick, Small side effects, the side effect of no conventional antidepressant agents, therefore, can be used as the drug candidate of excellent depression at the shortcomings of such as inducing epilepsy, incoordination.
Description
Technical field
The present invention relates to pharmaceutical fields, more particularly to purposes of the ganoderic acid A in depression.
Background technology
Depression has become the common disease and frequently-occurring disease of modern society, and incidence is also constantly increasing.Illness is with mood
Low, interest decline, retardation of thinking and speech are reduced with action and are characterized, and Serious depression has world-weary or suicide thought.This
Class disease is painful caused by patient and its family members, and the loss caused by society, is that many other disease institutes are incomparable
's.According to the report that the World Health Organization (WHO) delivers, the disturbance of emotion has become the fourth-largest illness in the world, global suppression at present
Strongly fragrant disease patient is up to 3.4 hundred million people.Depression is about 4% in Chinese incidence at present.Chinese at least 26,000,000 people are with suppression
Strongly fragrant disease, depression reach 62,200,000,000 yuans in total financial burden caused by China.The U.S. is estimated to be 17,000,000 people with depression
Disease, 3,000,000 people suffer from anxiety disorder, and the annual expense for treating the disturbance of emotion is up to 44,000,000,000 dollars (coronary heart disease is 43,000,000,000 dollars).
Past is in 40 years of disturbance of emotion research, especially strikingly its morbidity and mortality is high, it was reported that homicide rate is high
Up to 10% or more, there is 250,000 people suicide in China every year.
The drug being currently mainly used is serotonin reuptake inhibitors etc., slow using this kind of drug effect, action spectrum
Narrow, side effect is big, is easily recurred after drug withdrawal.Currently, rapid-action, Small side effects are badly in need of in anti depressant therapy field, it is more efficiently to control
Treat drug.
Current antidepressant and its weakness：Current antidepressants are broadly divided into three classes：I.e. monoamine oxidase presses down
Preparation, tricyclic antidepressants and heterocyclic antidepressant.Existing antidepressant far can not meet disease Man's Demands,
Shortcoming mainly concentrates on greatly the slow, antidepression that works and composes narrow, side effect is big, easily recurs etc..Develop rapid-action, antidepression
Spectrum extensively, the smaller new drug of toxic side effect, be unusual urgent need in this field, huge economy return will be brought.
Ganoderma lucidum [Ganoderma lucidum (Curtis:Fr.) P.Karst] belongs to Eumycota on classification of fungi
(Eumycota) Basidiomycetes (Basidiomycotina), Polyporaceae (Polyporaceae) ganoderma lucidum subfamily
(Ganodermatoideae) Ganoderma (Ganoderma).Ganoderma has 44 kinds of (including 21 kinds of ganoderma lucidum group, purple sesame groups in China
23 kinds), version Chinese Pharmacopoeia in 2005 is using two of which as the legal source of ganoderma lucidum:That is red sesame Ganoderma lucidum
(Leyss.ex Fr.) Karst. and purple sesame Ganoderma sinense is simultaneously known as ganoderma lucidum certified products.Ganoderma lucidum is plant ganoderma lucidum
Fructification, Gu claim " seocho ", are commonly called as " Radix Rhodiolae ", Japanese is called " Wan Nianrong ".Principle active component is spirit in ganoderma lucidum
Sesame triterpene compound.Ganoderic acid belongs to ganoderma lucidum triterpene compounds, and most study is Japan, followed by Chinese.To current
Until, comprehensive various reports, there are about 106 kinds for the triterpene compound being separated to from ganoderma lucidum sporocarp and conidia powder.
Since nineteen eighty-two Kubora.T et al. isolated ganoderic acid A (ganoderie from the fructification of ganoderma lucidum for the first time
AeidA) and ganoderic acid B (ganoderie aeidB) " since.Research has generally been carried out both at home and abroad for ganoderic acid.
Ganoderic acid A (Ganoderic acid A), red ganoderma acid A (Ganoderic lucidie acid A), molecule
Formula is C30H42O7, molecular weight 514.65, for chemical constitution as shown in Figure 1, ganoderic acid A is one kind in ganodenic acid, sesame is sour
There are many synonyms of English by A：Such as GANODERIC ACID A (P)；AIDS070759；AIDS-070759Aids070759
(25R)-7β,15α-Dihydroxy-3,11,23-trioxo-5α-lanost-8-en-26-oic acid；(7beta,
15alpha,25R)-7,15-Dihydroxy-3,11,23-trioxo-lanost-8-en-26-oic acid；Lanost-8-
en-26-oic acid,7,15-dihydroxy-3,11,23-trioxo-,(7.beta.,15.alpha.,25R)-(25R)-7
β,15α-Dihydroxy-3,11,23-trioxo-5α-lanost-8-en-26-oicaci.Chen Guoliang etc. (1995) is at home
The progress of ganoderic acid is referred in summary for the first time, wherein also it should be particularly mentioned that the health-care effect of ganoderic acid A, Japanese scholars are special
The preparation method of ganoderic acid in the preparation method of ganoderic acid and the mycelium of Liquid Culture is reported in profit；Wang Fangsheng etc. is from spirit
The dichloromethane dissolving of sesame is partially separated to obtain ganoderic acid DM.1999, Li Pingzuo etc. had studied point of ganoderic acid in zymotic fluid
From with purifying.Triterpenoid ganoderic acid A, B, C, D are isolated from the biological active component that the fructification methanol of red sesame extracts
The histamine release of the mast cell of the inductions such as concanavalin A can obviously be inhibited.Wang Mingyu etc. obtains 5 from ganoderma lucidum sporocarp
A triterpene component, ganoderic acid A therein is to 3 kinds of hepatic injuries caused by carbon tetrachloride, amine-galactose former times and BCG vaccine+lipopolysaccharides
Model mice has preferable hepatoprotective effect, can obviously reduce the Serum ALT and liver TG contents of animal pattern, and subtracts in various degree
Light animal hepatic injury.Ganodermanontriol and red ganoderma acid A (Ganolucidie acid A) can significantly inhibit mono- 1 types of HIV
The activity of protease, the characteristic of (AIDS virus) HIV-1 type viruses.Min etc. isolates Canoderi from Reishi sporule
Cacid, Canoderic acid and ganoderma lucidum ketone glycol (Ganoder manondiol) ganodermanontriol and red ganoderma acid A these
Ingredient can significantly inhibit the activity of HIV-1 type protease.Wu etc. isolates six kinds of triterpenes from ganoderma lucidum fruitbody ethanol extract
Class compound, pharmacological experiment show lucidenic acid A (ganoderic lucidenic acid) A and ganoderic acid (ganoderic
Acid) E has significant cytotoxic effect to liver cancer cells Hep G2 and Hep G2.2.15 and tumour cell P-338.From upper
Analysis is stated as can be seen that natural glossy ganoderma acid has its unique advantage, ganoderic acid A may be one in terms of antitumorization extremely to be had
The ingredient of effect.Ganoderic acid A also have treat angiocardiopathy, such as reduce blood fat, treat disease of digestive system, for another example hepatitis gastritis and
Duodenitis, protection liver and kidney, clearing heat and detoxicating；Respiratory disease can be treated again, such as alleviate asthma, bronchitis, branch
San bronchial asthma etc..The nervous system disease can also be treated, such as forgetful, insomnia is nervous, breathes difficult aging, beauty treatment.It studies at present and real
It tramples and shows that ganoderic acid A is very helpful to the health of the mankind, can be effectively prevented the oxidation of retina and the damage of photosensory cell,
And Central nervous system especially plays a protective role to brain, to effectively treat ischemia reperfusion injury, spinal cord damage
The central lesions such as wound, parkinson's syndrome, Alzheimer syndromes.Therefore, in distinguishing ganoderma lucidum Research on kinds,
Mostly by ganoderic acid content height as the foundation for distinguishing ganoderma lucidum quality good or not, this is very reasonable.
The 30 multinomial patents about ganoderic acid A purposes are had more than in the whole world at present, are seen attached list, but in existing literature or hair
There is not yet scholar is used to treat the report of depression about compound ganoderic acid A in bright patent.
Invention content
The present invention provides the ganoderic acid A anti-depression drugs being prepared as anti-depression drug and with it.This medicine
Object has many advantages, such as that antidepressant effect is notable, quick, Small side effects, and technical solution is as follows：
Purposes of the ganoderic acid A in preparing anti-depression drug, which is characterized in that the drug effect of the anti-depression drug is lived
Property ingredient be ganoderic acid A or ganoderic acid A derivative, the derivative refer to the salt of ganoderic acid A and pharmaceutical acceptable, ester or
Be saccharified the glucoside synthesized.
Purposes of the ganoderic acid A in preparing anti-depression drug, which is characterized in that the drug effect of the anti-depression drug is lived
Property ingredient includes the derivative of ganoderic acid A or ganoderic acid A, and the derivative refers to the salt of ganoderic acid A and pharmaceutical acceptable, ester
Or the glucoside of saccharification synthesis.
The anti-depression drug refers to the drug for preventing or treating depression.
The dosage form of the anti-depression drug is tablet, capsule, solution, suspension, injection or drip solution.
A kind of drug of depression, it is characterised in that：Its drug activity ingredient is ganoderic acid or the derivative of ganoderic acid A
The derivative of object, the ganoderic acid A refers to glucoside formed by the salt, ester or sugar of ganoderic acid A and pharmaceutical acceptable.
The depression refers to preventing or treating depression.
Its dosage form is tablet, capsule, solution, suspension, injection or drip solution.
The drug further includes acceptable auxiliary element in pharmaceutics.
The drug, further include have with ganoderic acid A or derivatives thereof with the use of when have positive effect to treatment depression
Drug ingedient, or make the stability-enhanced ingredients of ganoderic acid A.
A kind of method of depression, it is characterised in that：The medicament for the treatment of effective dose is provided on time to subject, it is described
The effective component of medicament includes the derivative of ganoderic acid A or ganoderic acid A, and the derivative refers to ganoderic acid A and can pharmaceutically connect
Salt, ester or the glucoside of saccharification synthesis of receipts.
The above method, the medicament for providing treatment effective dose on time refer to daily 0.5mg~1000mg ganoderic acids A/kg
Weight, administering mode are oral, instil or inject；Administration object is mammal, and the mammal includes people.
The dosage is daily 0.5mg-1000mg ganoderic acids A/1kg.
Inventor has found that ganoderic acid A has significant antidepressant effect to mammal.Through experimental studies have found that,
In mammal mouse experiment, (24 hours) are just provided with rapidly apparent and stronger anti-suppression to ganoderic acid A in a short time
Strongly fragrant disease effect, and antidepressant effect can continue to generate.There is inflammatory pain symptom in the universal main suit of patients with depression, such as has a headache, stomach
Bitterly, backache etc..Ganoderic acid it is antidepressant simultaneously, moreover it is possible to improve the inflammatory symptoms of patient.Many tumor disease patients are through changing
It treats, after radiotherapy in the treatment, complicated with depression, ganoderic acid A can play the role of antitumor and antidepressant simultaneously.Therefore small molecule chemical combination
Object ganoderic acid A can comprehensively improve various symptoms, including mental depression symptom, pain, inflammation of depressive patients etc..
Its antidepressant effect is notable in animal model, quickly and lasting.Antidepressant used at present takes effect very slowly, and one
As need several weeks.Industry is badly in need of the antidepressant of development fast onset.
Ganoderic acid A (Ganoderic acid A), red ganoderma acid A (Ganoderic lucidie acid A), molecule
Formula is C30H42O7, molecular weight 514.65.Its structure chart is as shown in Figure 1, be the red sesame from fungi Polyporaceae Ganoderma
One kind in the triterpenoid isolated in (Ganoderma lucidum karst), can be taken by the mankind, its poison for a long time
Side effect is not reported so far, and has no that the calm of conventional antidepressant agents, induction epilepsy, incoordination etc. lack in experiment process
Point.Ganoderic acid A can also be extracted from the red algae bacterium of culture and yeast.It has as quick, efficient, nontoxic secondary work
The potentiality of new antidepressant have very strong industrial applicibility and huge commercial value.
The drug screening test that the present invention uses for：Mouse forced swimming test and qutstanding tail test are common two kinds of animal rows
It is tested for desperate depression model, can preferably ensure the reliability of the selection result.
Mouse Forced Swim Test has been used for the screening test of many antidepressants.And most of there is clinical treatment work
Antidepressants are also proved that the dead time can be efficiently reduced in forced swimming test.It is so-called it is motionless refer to that " animal exists
Stop struggling in water, or be in floating state, only exposes nostril and keep breathing, only tiny limb motion, to keep head floating
In the water surface ".The drug of quasi- screening is given before testing.Being swum under anancastia due to animal prevents animal from escaping from severe ring
Border causes animal behavior desperate.Such model method is easy, reliably, is widely used in the screening and evaluation of antidepression medicament.
Rat force swimming test is that mouse no longer struggles under outstanding shape of tail state, and the distinctive motionless state of peace and quiet, antidepression is presented
Medicine can be obviously shortened the duration of motionless state.When test, mouse tail is fixed with medical adhesive tape, is hung by the feet.Do not make mouse
Tail portion distortion folds.The meter record dead time.Stationarity indices is：" animal all limbs in addition to breathing are motionless ".Qutstanding tail test pair
Various antidepressants are very sensitive, and avoid the interference of temperature and animal movement dysfunction in swimming test, thus
When screening antidepressant with some mouse kinds, the result of forced swim test effectively can be verified and supplemented.
Purposes of the ganoderic acid A provided by the invention as anti-depression drug, is not limited to the ganoderma lucidum of structural formula as shown in Figure 1
Purposes of the acid in preparing depression, it is ability that ganoderic acid A, which is prepared into the salt of ganoderic acid A, ester or itself and glucoside formed by sugar,
The routine experiment technical ability that field technique personnel have, the salt of ganoderic acid A, ester or its there is phase with glucoside formed by sugar and ganoderic acid A
As drug action to be those skilled in the art can rationally expect, therefore the salt of ganoderic acid A, ester is also claimed in the present invention
Or its purposes with glucoside formed by sugar in preparing anti-depression drug.
Ganoderic acid A provided by the invention prepares the purposes of anti-depression drug, it is prepared obtained by anti-depression drug, can
Being added with the common sense based on the technical staff of pharmaceutical field not influences the auxiliary element of medicine effect, such as carrier, excipients.
Since the drug can be taken effect by modes such as oral, injection, subcutaneous embeddings, dosage form can be various.
Anti-depression drug provided by the invention can also be to be mixed with and other is used cooperatively with ganoderic acid or derivatives thereof
There is the drug ingedient of positive effect to treatment depression.
Since ganoderic acid A stability is poor, stabilizer can be added in those skilled in the art, as long as not influencing ganoderic acid A
The performance of drug effect, the anti-depression drug of gained is in the scope of protection of present invention.
Anti-depression drug provided by the present invention, the depression include two stages of prevention and treatment.
In the range of Patent Law allows, purposes of the ganoderic acid A in depression treatment is also claimed in the present invention,
The dosage range for reaching anti depressant therapy effect in animal model test is daily 0.5mg-1000mg/1kg.
Description of the drawings
The chemical structural formula of Fig. 1 ganoderic acids A,
Influences of Fig. 2 ganoderic acids A to Tail suspension test,
Ordinate：The tail-suspention test mouse dead time (% controls),
Abscissa：From a left side to being followed successively by：Ganoderic acid A controls, ganoderic acid A is low, ganoderic acid A high, imipramine control group, and third
Miaow piperazine.
As a result：CD1 male mices are after the intraperitoneal injection twenty four hours of the ganoderic acid A of various dose, high dose group
(12.5 mgs/kg) show significant antidepressant effect in Tail suspension test.(every group of animal 12-15, * t is examined
p<0.05)
Influences of Fig. 3 ganoderic acids A to mouse forced swimming test,
Ordinate：The forced swim test mouse dead time (% controls),
Abscissa：From a left side to being followed successively by：Ganoderic acid A controls, ganoderic acid A is low, ganoderic acid A high, imipramine control group, and third
Miaow piperazine；
As a result：CD1 male mices are after the intraperitoneal injection three days of the ganoderic acid A of various dose, in mouse forced swimming test reality
Antidepressant effect is shown in testing.This antidepressant effect can compare favourably with traditional antidepressant imipramine.(every group dynamic
Object N=12-15, * t examine p<0.05).
Specific embodiment
Following embodiments is only used for being described in detail and proving that the ganoderic acid A that the present invention is had found is new in depression
Purposes, and it is not limited to the present invention.
Embodiment 1：Influences of the ganoderic acid A to animal depression model tail-suspention test
Animal CD1 kind mouse, male, 25-35 grams of weight are carried by Beijing Vital River Experimental Animals Technology Co., Ltd.
For credit number:SCXK (capital) 2011-0011.Animal sub-cage rearing, drinking water is free, and feed is by Chinese Academy of Sciences's genetic research
Institute's Experimental Animal Center provides, the edible normal diet of experimental mouse.
Test drug：
Ganoderic acid A is purchased from Shanghai Fu Sheng Industrial Co., Ltd.s, 10 milligrams of packagings.
Ganoderic acid A mother liquors：Ganoderic acid A is dissolved in a small amount of straight alcohol and obtains 20ug/ul, is diluted again before injection.
Positive control Impamin (Imipramine hydrochloride) is Sigma Products, article No.
I7379, lot number O56K1380.
Experiment equipment：Bar, adhesive plaster, Sumsung Intelli-200m DVs (Samsung of South Korea), JUNSO is more
Function timer.
Experimental procedure：Male CD1 mouse are raised one week through adaptability, are divided into 5 groups, every group eight, respectively：Ganoderic acid A
Control group：Physiological saline adds 1.0% ethyl alcohol, is injected by 0.3ml/30g weight；Ganoderic acid A dosage groups：5mg/kg weight, ganoderma lucidum
Sour A is dissolved in physiological saline and adds 1.0% ethyl alcohol；Ganoderic acid A high dose groups：12.5mg/kg weight, ganoderic acid A are dissolved in physiological saline
Add 1.0% ethyl alcohol；Imipramine positive controls：15mg/kg weight, imipramine physiological saline solution；Imipramine control group：Physiology
Brine is injected by 0.3ml/30g weight.
By design dosage intraperitoneal injection when the morning 10.It is administered when the next morning 10, injection starts after 90 minutes
Tail-suspention test.
When Tail suspension test, mouse tail is sticked to away from 2 centimeters of tail point on a horizontal cross bar with medical proof fabric, is made
Animal is at projecting state, about 15 centimetres from desktop of head.Observation 6 minutes, the accumulative dead time after record in 4 minutes.
Stationarity indices is：" animal all limbs in addition to breathing are motionless.”
Statistical method：Experimental result indicates that two average of samples compare to be examined with t with mean value ± SE.
As a result see Fig. 2.The high dose group of ganoderic acid A can be obviously shortened small after 24 hours compared with blank control group
Mouse hangs the tail dead time.Wherein low dose group not yet works, and shows a dose response.The result shows that the ganoderma lucidum of high dose
Sour A can work in a short period of time.Can anti-mouse caused by forcing outstanding tail depressive symptom.
Compared with blank control group, dead time when ganoderic acid A dosage is 12.5 mgs/kg and blank control group phase
Than being reduced to 48.33 ± 8.89 (P by 86.15 ± 8.36s<0.05) 43.9%, is shortened.The ganoderic acid A of low dosage is shown
The trend of one reduction, but not yet apparent attenuating.
2 mouse forced swimming test of embodiment
Animal is CD1 kinds mouse male, is provided by Beijing Vital River Experimental Animals Technology Co., Ltd., credit number:
SCXK (capital) 2011-0011.The last week is tested by animal sub-cage rearing, light and shade period 12h/12h, 20~22 DEG C of room temperature, freedom
Diet.Feed is provided by Institute of Genetics, Academia Sinica's Experimental Animal Center.
Experimental drug：Ganoderic acid A, Impamin (Imipramine hydrochloride) is the same as real embodiment 1；Experiment
Instrument：Glass cylinder (high 20cm, diameter 14cm)；The open case of mouse (diameter 30cm, high 20cm, 16 decile of bottom)；Thermometer；
JUNSO Multifunctional time-meters.
Drug prepares with 1 tail-suspention test of embodiment.
Ganoderic acid A mother liquors：Ganoderic acid A is dissolved in ethyl alcohol and obtains 20ug/ul suspension, dispenses and preserves -80oC refrigerators, before injection
Ethyl alcohol and normal saline dilution are used again.
Experimental procedure：Animal pharmaceuticals are injected：CD1 mouse, 7 weeks ages, 25-35 grams of weight adapt to environment and start after a week
Experiment.Animal is grouped at random, shares 5 groups, every group of eight animals.10 points of every morning starts to be injected intraperitoneally.Injection volume is 0.3 milli
Rise/30 grams.
Ganoderic acid A blank control groups：Daily intraperitoneal injection of saline adds 1.0% ethyl alcohol, injection volume to be 0.3 milliliter/30
Gram；
Ganoderic acid A groups：It gives different amounts of ganoderic acid A and is dissolved in physiological saline and add 1.0% ethyl alcohol,
Low dosage ganoderic acid A：5mg/kg
High dose ganoderic acid A：12.5mg/kg.
Traditional antidepressants imipramine positive controls, imipramine are dissolved in physiological saline, and injection volume presses 15mg/kg.
Imipramine blank control group：Injecting normal saline, injection volume are 0.3 milliliter/30 grams.
Above-mentioned test group, intraperitoneal injection is primary daily, injects three days, third day starts forced swimming after injecting 90 minutes
Experiment.Forced swim test：Each group CD1 mouse are individually placed vertically in plexiglass cylinder (40cm × 14cm diameters), water
Deep 15cm, 23 DEG C of water temperature.Each administration group and control group are recorded a video 6 minutes, when comparing each group mouse and adding up motionless in latter 4 minutes
Between.
Dead time judges:Mouse swims in the water surface, does not make great efforts to climb out of cylinder, and only doing some must keep its head in water
The action in face.
Statistical analysis technique：People is analyzed according to unified standard analysis result.Experimental result indicates with mean value ± SE, two samples
This average compares to be examined with t.
The result shows that ganoderic acid A has stronger antidepressant effect.Compared with blank control group, ganoderic acid A high dose groups
Significantly shorten with the dead time in low dose group mouse forced swimming test 4 minutes, ganoderic acid A dosage is 5 milligrams per grams or 12.5 millis
Dead time when gram gram is reduced to 45.10 ± 8.35 seconds (P respectively compared with blank control group, by 99.42 ± 8.89s<
And 59.89 ± 8.81 seconds (P 0.05)<0.05) 54.63% and 39.76%, has been respectively shortened.As a result see Fig. 3.With the anti-suppression of tradition
Strongly fragrant medicine imipramine is compared, and the ganoderic acid A's of high dose and low dosage has comparable and stronger antidepressant effect.
Bibliography
1. Chen Ruo rues, in moral spring ganodenic acid Recent Advances of Chemical Constituents mouth Acta Pharmaceutica Sinicas, 1990,25 (12):940-
953.
2.Kubota T,Asaka Y,Miura l,et al.Struetures of ganoderie A and B,two
new lanostanetype bitter tritepenes from Ganderma lucidum(Fr.)Karst{J].Helv
Chim Acta,1982,65(2):611-619.
3. Osaka institute of materia medica, useful component ガ ノ デ Application リ acids The volume To spirit containing む び sesames crushed materials and び In
System methods [p]:Japan:Clear 61-194032,1986-05-2-194032,1986,05-28.
4. " System makes method [P] Japan for day Shu Leigong Co., Ltd., ガ ノ デ Application リ acids:Te Open flat 4304890,1992,
10-28.
5. Chen Guoliang, the clear effective component of glossy ganoderma Review Study edible fungi of china of Chen Xiao, 1995,14 (4):7-9.
6. Wang Fang gives birth to, the research work Acta Pharmaceutica Sinicas of ganoderma lucidum acrylic component in the ganoderma lucidum sporocarps such as Cai Hui, Yang Junshan,
1997,32(6):447-450.
7. Li Ping makees, in Zhang Kechang fermented hyphostroma of Ganoderma ganoderic acid isolate and purify and bioactivity detection is naturally produced
Object and research, 1999,11 (4):67-70
8. Zeng Xiangli, Bao Haiying Ganoderma lucidum triterpenes components are studied with Pharmacological Advancement fungus, 2004,2 (l):68-
77.
9. the horse cash gift, the medicinal and edible research food and fermentation industries of your China ganoderma lucidums of Yao, 1998,24 (l):62-66.
10. Wang Ming spaces, Liu Qiang, vehicle celebrate the influence medicines of bright equal 3 kinds of mouse liver injury models of ganoderma lucidum triterpene compounds pair
Learn journal, 2000,35 (5):326-329.
11.Byung-sun MIN,Jiang-Jing GAO,Norio NAKAMURA,et al.Triterpenes From
the Spores of Ganoderma lucidum and Their Cytotoxicity against Meth-A and L
LC Tumor Cells[J].Chem Pharm Bull,2000,48(7)：1026-1033.
12. the function of tumor inhibition of active ingredient ganoderic acid studies bacteriologies in the ganoderma lucidums such as Zhou Changyan, Tang Qingjiu, Yang Zhong
Report, 2004,23 (2):275-279.
13. king helps military, the extraction separation of the Ganoderma lucidum acidic components such as Yang Xinlin, Zhang Ligang and the Beijing bacteriostatic activity research reason
Work college journal, 2002,22 (1):125-128.
14. pornographic books and magazines engrave, the antitumor action Natural products researchs of the Ethanol-soluble And Acidic Components From Ganoderma Lucidums such as Yang Xinlin, Wang Bangwu with
Exploitation, 2004,16 (2):146-148.
15. ヒ-エ ィ チ エ ス Co., Ltd., angiogenesis inhibition agent [P] Japan:Te Open, 2004-196761,2004-
07-15.
16. Nihon University, Hair cancers give anti-dose [p] Japan:Te Open, 2005-35898,2005-02-10.
17. Nihon University, Hair cancers give anti-dose of [P] Japan:Te Open, 2006-22017,2006-01-26.
18.NishitobaT,SatoH,sakamuras,etal.AgrBiolChem,1985,49:1793.
19.Kohda H,Tokumoto W,Sakamoto K,et al.The biologieally aetive
Constituents of Ganoderma Lucidum(Fr.)Karst histaminerelease-in hibitory
triter Pene[J].Chem Pharm Bull,1985,33:1367-1374.
20.Morigiwa A,Kitabatake K,FujimotoY,et al.Chem Pharm Bull,2956,34:
3025-3028.
Komoda Y,Shimizu M,SonodaY,et al.Ganoderic aeid and its derivatives
as cholesterol synthesis inhibitors[J].Chem Pharm Bull,1989,37(2):531-533。
Claims (8)
1. purposes of the ganoderic acid A in preparing anti-depression drug, which is characterized in that the drug activity of the anti-depression drug
Ingredient is the derivative of ganoderic acid A or ganoderic acid A, and the derivative refers to the salt, ester or sugar of ganoderic acid A and pharmaceutical acceptable
The glucoside being combined to.
2. purposes according to claim 1, the dosage form of the anti-depression drug be tablet, capsule, solution, suspension or
Injection.
3. purposes according to claim 2, the injection refers to drip solution.
4. a kind of drug of depression, it is characterised in that：Its drug activity ingredient is the derivative of ganoderic acid A or ganoderic acid A,
The derivative of the ganoderic acid A refers to glucoside formed by the salt, ester or sugar of ganoderic acid A and pharmaceutical acceptable.
5. drug according to claim 4, the depression refers to preventing or treating depression.
6. drug according to claim 4 or 5, dosage form is tablet, capsule, solution, suspension or injection.
7. drug according to claim 6, the injection refers to drip solution.
8. drug according to claim 4 further includes acceptable auxiliary element in pharmaceutics.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410197934.9A CN105012356B (en) | 2014-04-30 | 2014-05-12 | Purposes of the ganoderic acid A in depression |
| PCT/CN2015/077691 WO2015165382A1 (en) | 2014-04-30 | 2015-04-28 | Use of ganoderic acid a for anti-depression |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014101833949 | 2014-04-30 | ||
| CN201410183394 | 2014-04-30 | ||
| CN201410197934.9A CN105012356B (en) | 2014-04-30 | 2014-05-12 | Purposes of the ganoderic acid A in depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105012356A CN105012356A (en) | 2015-11-04 |
| CN105012356B true CN105012356B (en) | 2018-10-16 |
Family
ID=54358176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410197934.9A Active CN105012356B (en) | 2014-04-30 | 2014-05-12 | Purposes of the ganoderic acid A in depression |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN105012356B (en) |
| WO (1) | WO2015165382A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111304091A (en) * | 2019-11-28 | 2020-06-19 | 昆明理工大学 | Method for improving ganoderic acid content in ganoderma lucidum cell culture |
| CN112263584B (en) * | 2020-10-30 | 2021-09-07 | 广东省微生物研究所（广东省微生物分析检测中心） | Application of ganoderic acid A and its derivatives or total triterpenes of Ganoderma in preparing medicine for treating eye diseases |
| CN112618552B (en) * | 2020-12-30 | 2021-11-23 | 首都医科大学 | Application of ganoderic acid A or derivative of ganoderic acid A in preparation of medicine for treating autism |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101077357A (en) * | 2006-05-25 | 2007-11-28 | 北京大学 | Application for extration of glossy ganoderma in preparing medicine and health products for treating and improving depression symptoms a variety of causes resulting sleep disorder |
| CN101574499A (en) * | 2009-06-05 | 2009-11-11 | 李振爽 | Capsule for calming heart and tranquilizing mind |
| CN102846756A (en) * | 2012-09-10 | 2013-01-02 | 李承平 | Group of lotus seed nerve soothing and spleen tonifying tablets |
-
2014
- 2014-05-12 CN CN201410197934.9A patent/CN105012356B/en active Active
-
2015
- 2015-04-28 WO PCT/CN2015/077691 patent/WO2015165382A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101077357A (en) * | 2006-05-25 | 2007-11-28 | 北京大学 | Application for extration of glossy ganoderma in preparing medicine and health products for treating and improving depression symptoms a variety of causes resulting sleep disorder |
| CN101574499A (en) * | 2009-06-05 | 2009-11-11 | 李振爽 | Capsule for calming heart and tranquilizing mind |
| CN102846756A (en) * | 2012-09-10 | 2013-01-02 | 李承平 | Group of lotus seed nerve soothing and spleen tonifying tablets |
Non-Patent Citations (1)
| Title |
|---|
| 紫芝和松衫灵芝化学成分研究及灵芝三萜酸的含量测定;刘超;《中国优秀硕士学位论文数据库 医药卫生科技辑》;20100715(第7期);第1页摘要第2段、第33页倒数第1段-第34页灵芝酸 A结构式、第37页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015165382A1 (en) | 2015-11-05 |
| CN105012356A (en) | 2015-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109276576B (en) | Application of ganoderma leucocontextum polysaccharide in preparation of antitumor drugs | |
| CN105395919B (en) | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof | |
| WO2018113027A1 (en) | Application of bilobalide as synergist in preparation of drugs for preventing cranial nerve injury diseases | |
| CN104367600A (en) | Application of Antrodia camphorata extract in preparing medicine for regulating Th17 cells or treating diseases related to Th17 cell regulation | |
| CN105012356B (en) | Purposes of the ganoderic acid A in depression | |
| JP5114199B2 (en) | Method for producing lacquer extract and pharmaceutical composition containing the same | |
| CN103860530A (en) | Application of astaxanthin as antidepression medicine | |
| CN103980197B (en) | Spina Date Seed alkaloid monomer composition acid Lee alkali and preparation method thereof and application | |
| CN102370695B (en) | Qinglongyi active extract, its preparation method and its application | |
| CN109045035B (en) | Application of 7- (2, 2-dimethyl-3-butenamido) -octahydro phenylquinoline acetate in preparation of medicine for treating liver diseases | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| CN106905281A (en) | Suppress flavone compound of acetyl and butyrylcholine esterase and application thereof in thick fruit precipice beans rattan | |
| CN101143157A (en) | Tyrosol and tyrosol bypass salidroside plant extraction and preparation and use thereof | |
| CN102178721B (en) | Application of fiveleaf gynostemma herb suspension and extract to preparation of drug for treating and resisting depression | |
| CN115089622B (en) | Celery exosome composition and preparation method and application thereof | |
| CN102020623B (en) | Butterbur extract as well as preparation method and application thereof | |
| CN107648346A (en) | Application of the safron based composition in preparing treatment or improving the medicine of depression | |
| CN103860578A (en) | Use of lentinan as antidepressant drug | |
| CN104000820B (en) | Application of demethyleneberberine in preparation of drugs for preventing and/or treating ulcerative colitis | |
| CN103622988B (en) | Cordycepin purposes in the medicine preparing depression and the Fast Anti antidepressant agents being prepared thereof | |
| CN1246326C (en) | Pineapple flavonoid glycoside compound and its use | |
| CN102379873B (en) | Acute general Parkinson's disease monkey model and medicament screening method thereof | |
| CN105768095A (en) | Health food composition for improving immunity and preparation thereof | |
| CN1068790C (en) | Medicinal composition containing total saponin extracted from stem and leaves of American ginseng | |
| CN105796581A (en) | Application of paeoniflorin to preparation of medicine for regulating and controlling cholinergic anti-inflammatory pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220606 Address after: 102218 304, 87 / F, gongyuanli, East 1st District, Tiantongyuan, Changping District, Beijing Patentee after: Luo Yongqiang Address before: Room b273, building 1, No. 29, Academy of life sciences Road, Science Park, Changping District, Beijing 102206 Patentee before: BEIJING GRAGEN BIOTECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231206 Address after: Floor 3, Building 402, Zone 1, Tiantong Dongyuan, Dongxiaokou Town, Changping District, Beijing, 102218 Patentee after: Beijing Yasheng Bohou Biotechnology Development Center Address before: 102218 304, 87 / F, gongyuanli, East 1st District, Tiantongyuan, Changping District, Beijing Patentee before: Luo Yongqiang |